IGF1 and atypical Rett syndrome: Preclinical mouse models of Rett syndrome support this concept, as treatment of adult animals with mTOR-activating IGF-1 reduced anxiety levels and increased exploratory behaviors, suggesting that targeting mTOR can have an effect outside of the fetal developmental window (Castro et al., 2014).